Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A rush to market in the US and a trickle in Europe

This article was originally published in Clinica

Executive Summary

The defining development for medtech companies in 1996 was the rush of US development-stage businesses to the stock market during the first half of the year. This was followed by what must have been considerable disappointment for many early investors during the second half of the year when many newly-floated companies performed badly. Of the 46 initial public offerings in the US, the share price of 10 companies halved by December. Only 18 managed an increase, but three more than doubled in value between their flotation and December.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT089875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel